JEDIs for Survival Dinner

$100,000 presented to fund rare cancer research

At the foundation’s October 2022 Annual Dinner, Honorary co-chair Tiffany Taxel thanked our generous donor community and presented $100,000 to the Columbia University Herbert Irving Comprehensive Cancer Center. Its groundbreaking rare cancer research programs will accelerate scientific discovery toward the day when rare cancer patients have the same hope for treatments and potential cures as patients with common cancers.

Meet Our Esteemed 2022 JEDI Award Recipients

Also at the dinner, we introduced our 2022 JEDI Award honorees and are thrilled to announce the foundation’s new Medical Advisory Board Chairman is none other than JEDI Award honoree Dr. Gary Schwartz. A board-certified medical oncologist, internist and chief of Columbia University Medical Center’s Division of Hematology and Oncology, he directs a lab focusing on the identification of new targeted agents for cancer therapy, translational and clinical research.

JEDI Innovator in Rare Cancer Science honoree Gary Schwartz, MD is a is a recognized leader in the field of translational research and has been able to bridge the clinical and basic science elements of drug development.

JEDI Rare Cancer Agent of Change honoree Greg Simon, JD is is a visionary strategist, dynamic speaker and writer, and expert analyst of emerging trends in healthcare, drug development, and patient advocacy.

More news & events

How Rare Cancer Research Revolutionizes Treatment Across All Cancer Types

Jed Ian Taxel's parents: Mark and Linda Taxel. Mark serves as chairman and CEO of the foundation in Jed's name.

JEDI Rare Cancer Foundation $5 million commitment launches CURE: The Rare Cancer Initiative 

More healthy survivors, less family heartbreak

Your generous donation is an investment in ending rare cancer as we know it.

We accelerate discovery

Subscribe to our Quarterly Updates

Learn about lifesaving rare cancer research, foundation news, events, and discoveries that make a real, measurable difference in the lives of rare cancer patients and their families.

Your Voice Matters

Comment, Like, Share & Follow Us on Social Media.

Together, we can take action against rare cancer and help save lives.

Platinum Transparency 2023 Candid

The Jed Ian Taxel Foundation for Rare Cancer Research | P.O. Box 683501 Park City, Utah 84068

The Jed Ian Taxel Foundation for Rare Cancer Research, Inc. is a 501 (C)(3) Non-Profit Organization, accepting Tax Deductible donations from individuals, corporations, family-advised funds and foundations. Federal Tax ID 86-2610819

DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

© 2024 All Rights Reserved.
new york web designers

Subscribe to our Quarterly Updates

Learn about lifesaving rare cancer research, foundation news, events, and discoveries that make a real, measurable difference in the lives of rare cancer patients and their families.